Article Text

Download PDFPDF
Charcot–Marie–Tooth disease in Northern England
  1. Charlotte Foley1,
  2. Ian Schofield2,
  3. Gail Eglon1,
  4. Geraldine Bailey1,
  5. Patrick F Chinnery1,
  6. Rita Horvath1
  1. 1Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
  2. 2Department of Neurology, Newcastle University, Newcastle upon Tyne, UK
  1. Correspondence to Dr Rita Horvath, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK; rita.horvath{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Charcot–Marie–Tooth disease (CMT) is a group of inherited disorders of the peripheral nerves.1 Clinical diagnosis of CMT can be made fairly accurately, and the clinical classification is very helpful in the identification of new disease genes. Thus far, approximately 40 genes have been implicated in CMT, but at present only a limited number of genes can be routinely tested worldwide, including the UK (

All types of CMT are thought to affect approximately 5–40 per 100 000 individuals.2 A previous epidemiological study in the northeast of England in 1978 identified a lower point prevalence of CMT of 4.9 per 100 000.3 We re-evaluated the prevalence of CMT in this region, and report prevalence data for hereditary neuropathy with liability to pressure palsies (HNPP) in Northern England for the first time.

Patients and methods

The population of Northern England (Northumberland, Durham, Cumbria, parts of Yorkshire and Lancashire) is estimated at 2.99 million people with 259 500 in Newcastle upon Tyne, based on the 2001 UK census (Office of National Statistics; The Northern Genetics Service is defined by the boundaries of primary care trusts (online supplementary material) and the Newcastle upon Tyne Hospitals Foundation Trust. We identified patients in the Northern region who were alive on the prevalence day (1 September 2010) and had a clinical diagnosis of CMT through three prospective databases curated …

View Full Text


  • Funding This work was supported by the Medical Research Council Translational Neuromuscular Centre. RH is supported by the Medical Research Council (G1000848) and the Academy of Medical Sciences, UK (BH090164). PFC is a Wellcome Trust Senior Fellow in Clinical Science, and also receives funding from the Parkinson's Disease Society (UK), the Medical Research Council Translational Muscle Centre and the UK NIHR Biomedical Research Centre in Ageing and Age-related Disease.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was approved and performed under the ethical guidelines issued by our institutions for clinical studies.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The corresponding author declares that all authors and contributors have agreed to conditions about data sharing noted on the Authorship Agreement Form.